The penetration of tobramycin sulfate (nebramycin factor 6) into normal lower respiratory tract secretions was studied in a dog model. After a 1.7 mg/kg intravenous dose of tobramycin, the antibiotic was detected promptly in bronchial secretions, but the peak bronchial secretion concentration was not usually reached until 2 h after injection (mean level 1.15 ,ug/ml). The maximum tobramycin concentration in bronchial fluids was equal to the mean inhibitory concentrations that have been reported for about 80% of Pseudomonas isolates.
Tobramycin (nebramycin factor 6) is a new aminoglycoside antibiotic which has many properties in common with gentamicin (4) . In comparison with gentamicin, several studies have shown tobramycin to have greater in vitro activity against Pseudomonas (2, 5, 6, 8) . Since Pseudomonas infections of the lower respiratory tract are difficult to treat and are often fatal (7; J. E. Pennington, H. Y. Reynolds, and P. P. Carbone, Amer. J. Med., in press) despite the use of appropriate antibiotic therapy, an antibiotic with increased antibacterial activity against this microorganism would be valuable. In the present study, tobramycin concentrations in serum and bronchial secretions of normal dogs have been measured to determine the levels that can be obtained in bronchial secretions and to examine the penetration of the antibiotic into secretions of the lower respiratory tract.
MATERIALS AND METHODS
The canine model used for obtaining serum and bronchial secretion specimens has been described (5a) and was used in this study. Five American foxhounds (approximately 20 kg) were anesthetized with 2.5% sodium thiamylal and intubated with an endotracheal tube. Subcutaneous pilocarpine hydrochloride (0.5 mg/kg every 45 min) was given to stimulate bronchial secretion (about 1 ml/h) to insure an adequate collection of frequent bronchial specimens. Based upon protein analyses of bronchial secretions before and after pilocarpine stimulation and the small volumes of bronchial secretions produced with stimulation, significant dilution of the antibiotic in respiratory fluids did not occur. After an intravenous injection of tobramycin (given over a several-minute interval), serial blood (3 ml) and bronchial secretion specimens were obtained during an ensuing 2-or 3-h period. The bronchial secretion specimens were aspirated via the endotracheal tube by using a small-bore (1.25 mm) plastic catheter which was inserted to a maximal depth within a main-stem bronchus. Each bronchial secretion specimen was approximately 0.5 ml in volume; the pH was about 8.0. Serum was obtained from clotted blood and the sera and bronchial secretions were either assayed immediately or quickly frozen and stored at -20 C until used. Storage of samples for periods up to 2 weeks did not cause deterioration of tobramycin activity.
Tobramycin sulfate (lot no. CT-2194-2H, supplied by Eli Lilly and Co., Indianapolis, Ind.) was given in a single intravenous dose. The suggested maximal human dosage of tobramycin sulfate is 5 mg per kg per 24 h in divided doses or 1.7 mg per kg per 8-h interval. Therefore, the amount given to the 20-kg dog was approximately 35 mg. The intravenous injection of tobramycin was given over a shorter period of time (several minutes) than would be advocated for human administration to deliberately create the maximal concentration gradient between serum and intrabronchial fluids.
Tobramycin concentrations in serum and bronchial secretions were measured with the cup-plate bioassay method described by Bennett et al. (1) . The assay organism used was a Bacillus subtilis spore suspension (Difco Laboratories, Detroit, Mich.) incorporated into 250 and hepatic antibiotic clearances. We have presented an animal model which allows the simultaneous measurement of antibiotics in the serum and bronchial secretions in an attempt to study some features of the kinetics of antibiotic penetration and persistence in lung secretions. The intent of this work is to better quantitate levels of antibiotics in the bronchial secretions so that adjustments in the administration of parenteral antibiotics might be made. Immediately after intravenous infusion, the tobramycin concentration is high in serum and it appears promptly in bronchial secretions. The maximal gradient for diffusion of the antibiotic from the intravascular compartment to the respiratory secretions has been established. It might be expected that the highest tobramycin concentrations in bronchial specimens would occur in the early samples, particularly for an aminoglycoside antibiotic which, presumably, is not highly bound to intravascular protein. However, tobramycin levels in these secretions accumulated slowly in most of the dogs studied and reached peak concentrations 2 h after infusion. Serum antibiotic levels, in contrast, declined appreciably during this intervAl, reflecting normal renal clearance of the drug. In addition to passive diffusion of tobramycin into bronchial secretions, a process of active transport may be operant. This possibility is under further investigation.
To assess the value of tobramycin in treating bronchitis or bronchopneumonia, or both, due to Pseudomonas aeruginosa, one might compare the concentrations obtained in bronchial fluids ANTIMICROB. AG. CHEMOTHER. with the known minimal inhibitory concentrations of tobramycin for Pseudomonas pathogens. These values have been reported to include a wide range. In one study, 99% of Pseudomonas were inhibited at 0.4 qg/ml and 80% were inhibited at 0.1 ug/ml (2) ; likewise another group reported that 97% of Pseudomonas were inhibited at 0.39 ,g/ml and 83% were inhibited at 0.20 yg/ml (3). However, a contrasting report stated that only 55% of Pseudomonas strains were inhibited at 0.25 ,g of tobramycin per ml and 1 ,gg/ml was needed to inhibit 84% of Pseudomonas (8) . Until there is more experience with this drug, the values given for usual minimal inhibitory concentrations of tobramycin for Pseudomonas will vary. However, it seems that concentrations of this antibiotic obtained in bronchial secretions may inhibit over 80% of Pseudomonas pathogens (and perhaps closer to 90%).
An important question is whether tobramycin offers any advantage over gentamicin in treating infections of the lower respiratory tract. In the present study, tobramycin was given in a milligram-per-kilogram dose based upon the maximum tolerated by humans. In a previous study (5a) 
